The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States

Cancer

Volumn 118, Issue 24, 2012, Pages 6226-6233

  Sahasrabuddhe, Vikrant V ^a   Shiels, Meredith S ^a   McGlynn, Katherine A ^a   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

acquired immunodeficiency syndrome; epidemiology; hepatitis C virus; hepatocellular carcinoma; human immunodeficiency virus

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHILD; COMBINATION CHEMOTHERAPY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; STANDARDIZED INCIDENCE RATIO; UNITED STATES; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84870700659     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27694     Document Type: Article

References (45)

1. McGlynn KA, London WT,. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15: 223-243, vii-x.
2. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ,. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr. 2002; 31: 536-541.
3. Puoti M, Rossotti R, Garlaschelli A, Bruno R,. Hepatocellular carcinoma in HIV hepatitis C virus. Curr Opin HIV AIDS. 2011; 6: 534-538.
4. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011; 25: 899-904.
5. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2551-2559.
6. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB,. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004; 164: 2349-2354.
7. Bongiovanni M, Tordato F,. Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management. Curr HIV Res. 2007; 5: 490-498.
8. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K,. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011; 377: 1198-1209.
9. Pol S, Lebray P, Vallet-Pichard A,. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004; 38 (suppl 2): S65-S72.
10. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103: 753-762.
11. Sulkowski M,. Hepatocellular carcinoma in HIV-infected patients comes of age: the convergence of epidemiology and treatment effectiveness. J Hepatol. 2009; 50: 655-658.
12. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20: 1645-1654.
13. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123: 187-194.
14. Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE,. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag. 2011; 38: 201-205.
15. Simard EP, Pfeiffer RM, Engels EA,. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010; 170: 1337-1345.
16. Sherman KE, Rouster SD, Chung RT, Rajicic N,. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis. 2002; 34: 831-837.
17. Sulkowski MS, Thomas DL,. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003; 138: 197-207.
18. Shaw JJ, Shah SA,. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol. 2011; 5: 365-370.
19. Wasley A, Grytdal S, Gallagher K,. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ. 2008; 57: 1-24.
20. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ,. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002; 156: 761-773.
21. Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS,. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am J Epidemiol. 2007; 165: 1443-1453.
22. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S,. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011; 31: 1090-1101.
23. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010; 202: 192-201.
24. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360: 1921-1926.
25. Parry CD, Patra J, Rehm J,. Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction. 2011; 106: 1718-1724.
26. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R,. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007; 46: 194-199.
27. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A,. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010; 26: 511-518.
28. Sanyal A, Poklepovic A, Moyneur E, Barghout V,. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010; 26: 2183-2191.
29. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA,. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54: 463-471.
30. Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic [serial online]. PLoS One. 2010; 5: e10106.
31. Satlin MJ, Hoover DR, Glesby MJ,. Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS. 2011; 25: 5-12.
32. Sterling RK, Contos MJ, Smith PG, et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology. 2008; 47: 1118-1127.
33. Feeney ER, Mallon PW,. Insulin resistance in treated HIV infection. Best Pract Res Clin Endocrinol Metab. 2011; 25: 443-458.
34. Mallet V, Vallet-Pichard A, Pol S,. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011; 31 (suppl 1): 135-139.
35. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33: 562-569.
36. Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008; 22: 2135-2141.
37. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D,. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009; 10: 1152-1159.
38. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD,. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000; 283: 74-80.
39. Tarwater PM, Mellors J, Gore ME, et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol. 2001; 154: 675-681.
40. Park LS, Tate JP, Justice AC, et al. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2512-2517.
41. Mehta SH, Buckle GC,. Assessment of liver disease (noninvasive methods). Curr Opin HIV AIDS. 2011; 6: 465-471.
42. Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS. 2011; 25: 777-786.
43. Poordad F, Khungar V,. Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care. 2011; 17 (suppl 4): S123-S130.
44. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D,. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003; 36: 97-100.
45. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006; 20: 2361-2369.